Skip to main content
Top
Published in: International Urology and Nephrology 8/2014

01-08-2014 | Nephrology - Original Paper

Should screening of renal markers be recommended in a working population?

Authors: Arjan van der Tol, Wim Van Biesen, Guy De Groote, Paul Verbeke, Frans Vermeiren, Kathleen Eeckhaut, Raymond Vanholder

Published in: International Urology and Nephrology | Issue 8/2014

Login to get access

Abstract

Introduction

It is debated whether the general population should be screened for kidney disease. This study evaluated whether screening of albuminuria and estimated glomerular filtration rate (eGFR) in a working population should be recommended to detect subjects with chronic kidney disease.

Methods

The unreferred renal insufficiency study is a cross-sectional study in 1,398 workers aged 17–65. Markers of cardiovascular and renal disease were measured. Cardiovascular risk (CVR) was defined by hypertension (n = 416), diabetes (n = 45), dyslipidemia (n = 159) and/or history of a cardiovascular event (n = 10).

Results

In our population, 5 % of the workers had microalbuminuria, 0.5 % had macroalbuminuria and <0.1 % had eGFR <60 ml/min/1.73 m2. All workers with an eGFR <60 ml/min/1.73 m2 and/or macroalbuminuria (8/8) had at least one CVR factor, whereas this was the case in only half of workers with microalbuminuria (36/73, p = 0.007). In workers without CVR factors, the presence of microalbuminuria was associated with low body mass index (BMI, p < 0.001) or physiochemical exposure risk (p < 0.001).

Conclusions

Screening of renal markers in a working population, identified only a few subjects with an eGFR <60 ml/min/1.73 m2 or macroalbuminuria. Although microalbuminuria was more prevalent, it might not necessarily indicate kidney disease, as it may have a completely different meanings depending of the phenotype of the screened subjects. Besides underlying CVR factors, microalbuminuria was also associated with low BMI in absence of any risk factor, suggesting presence of benign postural proteinuria. In addition, microalbuminuria also seemed to be related to physicochemical exposure. In view of the impossibility to further analyze this finding in the present study, the meaning of this observation needs to be further investigated.
Appendix
Available only for authorised users
Literature
3.
go back to reference Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J. (2011) Chronic Kidney Disease Prognosis C. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80:93–104. http://www.ncbi.nlm.nih.gov/pubmed/21289597 Gansevoort RT, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J. (2011) Chronic Kidney Disease Prognosis C. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80:93–104. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21289597
6.
go back to reference Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081. http://www.ncbi.nlm.nih.gov/pubmed/20483451 Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20483451
8.
go back to reference Fink HA, Ishani A, Taylor BC, Greer NL, Macdonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ. (2012) Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the u.s. Preventive services task force and for an american college of physicians clinical practice guideline. Annals of internal medicine 156:570–581. http://www.ncbi.nlm.nih.gov/pubmed/22508734 Fink HA, Ishani A, Taylor BC, Greer NL, Macdonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ. (2012) Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the u.s. Preventive services task force and for an american college of physicians clinical practice guideline. Annals of internal medicine 156:570–581. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22508734
9.
go back to reference van der Velde M, Halbesma N, de Charro FT, Bakker SJL, de Zeeuw D, de Jong PE, Gansevoort RT. (2009) Screening for Albuminuria Identifies Individuals at Increased Renal Risk. Journal of the American Society of Nephrology 20:852–862.<Go to ISI>://000264831300023 van der Velde M, Halbesma N, de Charro FT, Bakker SJL, de Zeeuw D, de Jong PE, Gansevoort RT. (2009) Screening for Albuminuria Identifies Individuals at Increased Renal Risk. Journal of the American Society of Nephrology 20:852–862.<Go to ISI>://000264831300023
10.
go back to reference Romundstad S, Holmen J, Kvenild K, Aakervik O, Hallan H. (2003) Clinical relevance of microalbuminuria screening in self-reported non-diabetic/non-hypertensive persons identified in a large health screening–the Nord-Trondelag Health Study (HUNT), Norway. Clin Nephrol 59:241–251. http://www.ncbi.nlm.nih.gov/pubmed/12708563 Romundstad S, Holmen J, Kvenild K, Aakervik O, Hallan H. (2003) Clinical relevance of microalbuminuria screening in self-reported non-diabetic/non-hypertensive persons identified in a large health screening–the Nord-Trondelag Health Study (HUNT), Norway. Clin Nephrol 59:241–251. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​12708563
11.
go back to reference Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, Smith C. (2010) Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess 14:1–184. http://www.ncbi.nlm.nih.gov/pubmed/20441712 Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, Smith C. (2010) Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess 14:1–184. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20441712
14.
go back to reference Warram JH, Gearin G, Laffel L, Krolewski AS. (1996) Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. Journal of the American Society of Nephrology 7:930–937. <Go to ISI>://A1996UT21600017 Warram JH, Gearin G, Laffel L, Krolewski AS. (1996) Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. Journal of the American Society of Nephrology 7:930–937. <Go to ISI>://A1996UT21600017
15.
go back to reference Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS. (2012) Investigators C-E. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New Engl J Med 367:20–29. <Go to ISI>://000305979400002 Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS. (2012) Investigators C-E. Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New Engl J Med 367:20–29. <Go to ISI>://000305979400002
16.
go back to reference Cleeman JI, Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard WJ, Hunninghake DB, Illingworth DR, Luepker RV, McBride P, McKenney JM, Pasternak RC, Stone NJ, Van Horn L, Brewer HB, Ernst ND, Gordon D, Levy D, Rifkind B, Rossouw JE, Savage P, Haffner SM, Orloff DG, Proschan MA, Schwartz JS, Sempos CT, Shero ST, Murray EZ. (2001) Expe NCEP. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama-Journal of the American Medical Association 285:2486–2497. <Go to ISI>://000168547600031 Cleeman JI, Grundy SM, Becker D, Clark LT, Cooper RS, Denke MA, Howard WJ, Hunninghake DB, Illingworth DR, Luepker RV, McBride P, McKenney JM, Pasternak RC, Stone NJ, Van Horn L, Brewer HB, Ernst ND, Gordon D, Levy D, Rifkind B, Rossouw JE, Savage P, Haffner SM, Orloff DG, Proschan MA, Schwartz JS, Sempos CT, Shero ST, Murray EZ. (2001) Expe NCEP. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama-Journal of the American Medical Association 285:2486–2497. <Go to ISI>://000168547600031
17.
go back to reference Genuth S, Alberti KGMM, Bennett P, Buse J, DeFronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. (2003) Classificat ECD. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167. <Go to ISI>://000186269100030 Genuth S, Alberti KGMM, Bennett P, Buse J, DeFronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. (2003) Classificat ECD. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167. <Go to ISI>://000186269100030
18.
go back to reference Hillege HL, Janssen WMT, Bak AAA, Diercks GFH, Grobbee DE, Crijns H, van Gilst WH, de Zeeuw D, de Jong PE, Prevend Study G. (2001) Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. Journal of Internal Medicine 249:519–526. <Go to ISI>://000169568600005 Hillege HL, Janssen WMT, Bak AAA, Diercks GFH, Grobbee DE, Crijns H, van Gilst WH, de Zeeuw D, de Jong PE, Prevend Study G. (2001) Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. Journal of Internal Medicine 249:519–526. <Go to ISI>://000169568600005
19.
go back to reference Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS. (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35. <Go to ISI>://000222461800009 Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H, Appleyard M, Jensen JS. (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35. <Go to ISI>://000222461800009
22.
go back to reference Nguyen S, McCulloch C, Brakeman P, Portale A, Hsu CY. (2008) Being overweight modifies the association between cardiovascular risk factors and microalbuminuria in adolescents. Pediatrics 121:37–45. <Go to ISI>://000252096300006 Nguyen S, McCulloch C, Brakeman P, Portale A, Hsu CY. (2008) Being overweight modifies the association between cardiovascular risk factors and microalbuminuria in adolescents. Pediatrics 121:37–45. <Go to ISI>://000252096300006
23.
go back to reference Robinson RR, Coggins CH, Shapiro K, Cohen JJ, Harrington JT, Kassirer JP. (1980) Isolated Proteinuria in Asymptomatic Patients. Kidney International 18:395–406. <Go to ISI>://WOS:A1980KK18700014 Robinson RR, Coggins CH, Shapiro K, Cohen JJ, Harrington JT, Kassirer JP. (1980) Isolated Proteinuria in Asymptomatic Patients. Kidney International 18:395–406. <Go to ISI>://WOS:A1980KK18700014
25.
go back to reference Cho LS, Choi YM, Kang HH, Park SJ, Lim JW, Yoon TY. (2001) Diagnosis of nut-cracker phenomenon using renal Doppler ultrasound in orthostatic proteinuria. Nephrol Dial Transplant 16:1620–1625. <Go to ISI> ://WOS:000170410000019 Cho LS, Choi YM, Kang HH, Park SJ, Lim JW, Yoon TY. (2001) Diagnosis of nut-cracker phenomenon using renal Doppler ultrasound in orthostatic proteinuria. Nephrol Dial Transplant 16:1620–1625.  <Go to ISI> ://WOS:000170410000019
29.
go back to reference Naderi ASA, Reilly RF. (2008) Primary Care Approach to Proteinuria. J Am Board Fam Med 21:569–574. <Go to ISI>://000260721500014 Naderi ASA, Reilly RF. (2008) Primary Care Approach to Proteinuria. J Am Board Fam Med 21:569–574. <Go to ISI>://000260721500014
Metadata
Title
Should screening of renal markers be recommended in a working population?
Authors
Arjan van der Tol
Wim Van Biesen
Guy De Groote
Paul Verbeke
Frans Vermeiren
Kathleen Eeckhaut
Raymond Vanholder
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 8/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-014-0718-x

Other articles of this Issue 8/2014

International Urology and Nephrology 8/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine